EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis

Stefan Siebert iD, Laura C Coates iD, Georg Schett iD, Siba P Raychaudhuri iD, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty iD, May Shawi iD, Frederic Lavie iD, Mohamed Sharaf iD, Miriam Zimmermann iD und 5 weitere

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42803 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Stefan Siebert und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic, Interleukin-22, Interleukins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Research & Development, Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We assessed and compared immunologic differences and associations with clinical response to guselkumab, a fully human interleukin (IL)–23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) who were biologic‐naive or had inadequate response to tumor necrosis factor inhibitors (TNFi‐IR).

Methods

Serum biomarker levels at baseline and after treatment with guselkumab 100 mg every 8 weeks were compared between biologic‐naive (n = 251) and TNFi‐IR (n = 93) subgroups identified in the pooled DISCOVER‐1/DISCOVER‐2/COSMOS data set. Baseline biomarker levels determined by achievement of week 24 clinical responses (≥75%/90% improvement in Psoriasis Area and Severity Index [PASI 75/90], Investigator's Global Assessment [IGA] of psoriasis score 0/1 and ≥2‐point improvement], ≥20% improvement in American College of Rheumatology criteria [ACR20]) were compared between prior treatment subgroups.

Results

Baseline IL‐22, TNFα, and beta defensin‐2 (BD‐2) levels were significantly lower in biologic‐naive than in TNFi‐IR participants. With guselkumab, week 24 IL‐17A, IL‐17F, IL‐22, serum amyloid A, C‐reactive protein, IL‐6, and BD‐2 levels were significantly reduced from baseline in biologic‐naive and TNFi‐IR participants (≥1.4‐fold difference, nominal P < 0.05). Clinical responders to guselkumab exhibited significantly higher baseline levels of several biomarkers than nonresponders (IL‐17A, IL‐17F, BD‐2 in biologic‐naive PASI 90 responders; IL‐17A, BD‐2 in TNFi‐IR IGA 0/1 responders; IL‐22, BD‐2 in TNFi‐IR PASI 90 responders [nominal P < 0.05]) and trended higher in TNFi‐IR ACR20 responders.

Conclusion

Guselkumab modulates IL‐23 signaling and provides consistent pharmacodynamic effects in both biologic‐naive and TNFi‐IR PsA patients. Significantly elevated baseline IL‐22, TNFα, and BD‐2 levels and associations between baseline IL‐22, IL‐17A, and BD‐2 levels and skin responses to guselkumab suggest greater dysregulation of IL‐23/Th17 signaling in patients with TNFi‐IR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedArthritis, PsoriaticInterleukin-22InterleukinsInterleukin-17HumansMaleFemaleMiddle AgedAdultInterleukin-23Treatment OutcomeTumor Necrosis Factor InhibitorsBiomarkersSignal TransductionSerum Amyloid A ProteinInterleukin-23 Subunit p19Antirheumatic AgentsC-Reactive ProteinInterleukin-6Tumor Necrosis Factor-alpha

Substanzen

guselkumabAntibodies, Monoclonal, HumanizedInterleukin-22InterleukinsInterleukin-17Interleukin-23Tumor Necrosis Factor InhibitorsBiomarkersSerum Amyloid A ProteinInterleukin-23 Subunit p19

Autor:innen und Institutionen

  • University of Glasgow, Glasgow, UK.
  • University of Oxford, Oxford, UK.
  • Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
  • University of California Davis and Veterans Affairs Northern California Health Care System, Mather, California.
  • Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, and Drexel University College of Medicine, Philadelphia, Pennsylvania.

ORCID-Profile: Stefan Siebert, Laura C Coates, Georg Schett, Siba P Raychaudhuri, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Proton Rahman, Philip J Mease, Atul Deodhar

Förderung

  • Janssen Research & Development
  • Janssen Research and Development

Zitieren

APA

Siebert, S., Coates, L. C., Schett, G., Raychaudhuri, S. P., Chen, W., Gao, S., Seridi, L., Chakravarty, S. D., Shawi, M., Lavie, F., Sharaf, M., Zimmermann, M., Kollmeier, A. P., Xu, X. L., Rahman, P., Mease, P. J., & Deodhar, A. (2024). Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.42803

Vancouver

Siebert S, Coates LC, Schett G, Raychaudhuri SP, Chen W, Gao S, et al. Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis. Arthritis & Rheumatology. 2024. doi:10.1002/art.42803

BibTeX
@article{Siebert2024,
  author = {Siebert, Stefan and Coates, Laura C and Schett, Georg and Raychaudhuri, Siba P and Chen, Warner and Gao, Sheng and Seridi, Loqmane and Chakravarty, Soumya D and Shawi, May and Lavie, Frederic and Sharaf, Mohamed and Zimmermann, Miriam and Kollmeier, Alexa P and Xu, Xie L and Rahman, Proton and Mease, Philip J and Deodhar, Atul},
  title = {Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42803}
}
Kostenlos starten →